Results for tag: "Ilumya"

Ilumya (tildrakizumab-asmn) is a biologic drug used to treat moderate-to-severe plaque psoriasis in adults. It is a humanized monoclonal antibody that selectively binds to the p19 subunit of interleukin-23 (IL-23) and inhibits its interaction with the IL-23 receptor, thereby blocking the release of pro-inflammatory cytokines and chemokines. Ilumya is administered as a subcutaneous injection every 12 weeks. Ilumya is part of a growing market of psoriasis drugs, which includes biologics, small molecules, and topical treatments. Biologics are the most commonly prescribed psoriasis drugs, as they target specific pathways in the immune system to reduce inflammation. Small molecules are oral medications that can be taken daily or weekly, and topical treatments are creams, ointments, and shampoos that are applied directly to the skin. Some companies in the Ilumya market include Sun Pharmaceutical Industries, AbbVie, and Janssen Biotech. Show Less Read more